TNFα inhibitors, including etanercept, a soluble dimeric TNF-a receptor 2, and infliximab, a monoclonal antibody against TNFα, are used in the treatment of steroid-refractory GvHD [78,79]. This evidence concerns the gene TNF and graft versus host disease.